Natural products company ChromaDex receives an undisclosed amount of equity financing from DSM Venturing.
ChromaDex, a US-based phytochemicals and ingredient technology company, has received an undisclosed amount of equity financing from DSM Venturing, the corporate venture arm of Netherlands-based life sciences and material sciences company Royal DSM.
Frank Jaksch, chief executive officer and co-founder of ChromaDex, said: “It is with great pride and enthusiasm that we welcome DSM as a strategic investor in ChromaDex. We believe the investment demonstrates their confidence in the future of ChromaDex as well as our unique business model of…
